eGenesis vs Stipple Bio
Side-by-side comparison of AI visibility scores, market position, and capabilities
FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ months post-transplant. 69-gene-edited pig — most complex CRISPR ever.
About
eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes that trigger human rejection, adds human immune tolerance genes, and eliminates porcine endogenous retroviruses. The company received FDA clearance for its IND for EIGEN-2784 (a gene-edited pig kidney) for end-stage kidney disease, and its first transplant patient remained dialysis-free at more than 7 months post-transplant — the longest reported survival for a xenotransplantation recipient.
Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.
About
Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.